Inari Medical FY2025 EPS Estimate Raised by William Blair

Inari Medical, Inc. (NASDAQ:NARI) – William Blair increased their FY2025 earnings per share (EPS) estimates for Inari Medical in a research report issued on Thursday, October 31st. William Blair analyst M. Kaczor now anticipates that the company will post earnings of $0.18 per share for the year, up from their previous forecast of $0.13. William Blair has a “Outperform” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.74) per share.

NARI has been the topic of a number of other reports. Canaccord Genuity Group increased their price target on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, October 29th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 target price on the stock. Truist Financial upped their price target on shares of Inari Medical from $46.00 to $50.00 and gave the company a “hold” rating in a research report on Tuesday, October 29th. Piper Sandler lifted their price objective on Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday, October 29th. Finally, Leerink Partnrs upgraded Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Inari Medical has an average rating of “Hold” and an average price target of $58.89.

Inari Medical Trading Up 2.3 %

Shares of NASDAQ NARI opened at $50.05 on Monday. The stock’s 50-day moving average is $43.91 and its 200 day moving average is $46.31. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -37.07 and a beta of 0.96. Inari Medical has a 1-year low of $36.73 and a 1-year high of $67.13.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in NARI. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Inari Medical during the first quarter valued at approximately $30,000. GAMMA Investing LLC boosted its holdings in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after buying an additional 438 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares during the period. Covestor Ltd increased its stake in shares of Inari Medical by 30.2% in the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after acquiring an additional 376 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its position in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Insiders Place Their Bets

In related news, Director William Hoffman sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the transaction, the director now owns 643,296 shares in the company, valued at $29,482,255.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Inari Medical news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the transaction, the director now directly owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 131,000 shares of company stock worth $6,161,340. 10.60% of the stock is currently owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.